Synaptogenix, INC 10-Q quarterly reports

TAO Synergies reports Q1 2026 net income of $4.25 million, driven by unrealized gains on its Bittensor (TAO) cryptocurrency treasury holdings.

TAO Synergies Inc. reports a significant net loss for Q3 2025, driven by its pivot to an AI crypto treasury strategy and related expenses, while discontinuing prior drug development programs.

TAO Synergies Inc. has officially shifted its business strategy from biopharmaceuticals to a cryptocurrency treasury focused on Bittensor's TAO token, reporting a significant net loss of $17.1 million for the first half of 2025.

Synaptogenix reports a net income of $385,169 for Q1 2025, shifting from a loss in the previous year, while exploring strategic alternatives and managing cash reserves.

Synaptogenix's Q3 2024 report details financial results, ongoing clinical trials, and recent financing activities, including a new preferred stock offering.

Synaptogenix, Inc. reports a net loss of $1.48 million for the six months ended June 30, 2024, while continuing to advance its clinical development programs.

Synaptogenix reported its financial results for the first quarter of 2024, highlighting a decrease in net loss and ongoing clinical trial activities.